ImmuneRegen BioSciences Holdings Inc. Establishes Research Entity in Singapore
March 29 2004 - 6:28PM
PR Newswire (US)
ImmuneRegen BioSciences Holdings Inc. Establishes Research Entity
in Singapore Biotech Company to Test for Efficacy in Treating SARS,
Avian Flu, Toxic Inhalation SCOTTSDALE, Ariz., March 29
/PRNewswire-FirstCall/ -- IR BioSciences Holdings, Inc. (BULLETIN
BOARD: IRBH) , owner of biotechnology research and development
company ImmuneRegen BioSciences, Inc., today announced it has
established a research entity in Singapore and has created IMM
BioSciences Asia, Ltd. IR BioSciences Holdings, Inc. will license
the use of its proprietary compound Homspera through this new
entity for studies on the compound's efficacy in potentially
treating adverse effects of cancer, cigarette smoking, influenza,
SARS/Avian Flu, HIV among others. The future studies are expected
to be held at research labs located at Biopolis, a center for
biomedical sciences located in close proximity to the National
University of Singapore, University Hospital and the Singapore
Science Parks. The campus currently houses many mid-size and large
biotech companies, as well as several key government agencies,
publicly funded research institutes and R&D labs. "We chose
this facility very carefully," explains Michael K. Wilhelm, CEO of
ImmuneRegen BioSciences, Inc. "This facility mirrored our needs and
corporate direction. The overall design encourages strategic
assistance and fosters a collaborative culture among the private
and public research community, which is key in any research study.
We are currently working on securing the space and should be moving
ahead with our studies shortly." About ImmuneRegen BioSciences,
Inc. ImmuneRegen BioSciences, Inc. is a biotechnology company
engaged in the research and development of applications utilizing
modified Substance P, a naturally occurring immunomodulator.
Derived from homeostatic substance P, the company has named their
proprietary compound "Homspera." The Company's initial focus is on
the continuing development of Homspera for various applications for
use in improving pulmonary function and stimulating the human
immune system. For more information, please visit the Company's
website at http://www.immuneregen.com/. History of Homspera
ImmuneRegen's patents and continued substance P research are
derived from discoveries made during research funded by the Air
Force Office of Scientific Research in the early 1990s. During this
research, Dr. Mark Witten (ImmuneRegen co-founder and acting head
researcher) and his associates observed that the exposure of
animals to jet fuels resulted in pathological changes in the lung
and immune systems of those exposed. It was also observed that such
exposure resulted in depletion of substance P from the lungs of the
animals. These studies further showed that the administration of
substance P may help prevent and reverse the effects of jet fuel
exposure in the lungs, as well as protect and regenerate the immune
system. The immune findings led to early research on the treatment
of exposure to acute radiation and on the possible reversal of lung
damage caused by ARDS and cigarette smoke. Statements about the
Company's future expectations, including future revenues and
earnings, and all other statements in this press release other than
historical facts, are "forward-lookingstatements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934, and as that term is defined
in the Private Securities Litigation Reform Act of 1995. The
Company intends that such forward-looking statements be subject to
the safe harbors created thereby. The Company's actual results
could differ materially from expected results as a result of a
number of factors, including the uncertainties inherent in research
collaborations, clinicaltrials and product development programs,
the evaluation of potential opportunities, the level of corporate
expenditures, capital market conditions, and others set forth in
the Company's periodic report on Form 8-K as filed with the
Securities and Exchange Commission on July 7, 2003. DATASOURCE:
ImmuneRegen BioSciences, Inc. CONTACT: media, Michelle Derden of
Spelling Communications, +1-310-477-9500, ; or investors, Tony
Schor of InvestorAwareness, +1-847-945-2222, , both for ImmuneRegen
BioSciences Holdings Inc. Web site: http://www.immuneregen.com/
Copyright